The efficacy of disease-modifying therapies in patients with clinically isolated syndrome: a systematic review and network meta-analysis

Nature·Mar 11

This story is reported by Nature. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments

Neurology® Journals·Nov 24

2

In the Clinic-Multiple Sclerosis

Neurology Today·Oct 25

3

Disease-modifying treatment for multiple sclerosis in Poland in a European context: current practices and therapeutic strategies | Adamczyk-Sowa | Neurologia i Neurochirurgia Polska

Via Medica Journals·May 10

4

Multiple sclerosis: three trials to watch

Clinical Trials Arena·Oct 28

5

Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026

NeurologyLive·Jan 2

6

Update on clinical trials to study the efficacy of baricitinib as a disease-modifying therapy for T1D

Breakthrough T1D Canada·Mar 19

7

Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial

The Lancet·Oct 24

8

Shifting trends in initiation of disease-modifying therapies for multiple sclerosis

Truveta·Jul 16